Eloxx Pharmaceuticals, Inc. (ELOX) AI Stock Analysis

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for rare kidney diseases, including Alport syndrome, cystic fibrosis, and nephropathic cystinosis, as well as in preclinical stages for autosomal dominant polycystic kidney disease. It also maintains a collaboration with Almirall, S.A. to develop and commercialize ZKN-013 for rare skin diseases, including recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa.

Eloxx reported revenue of $75,000 in FY2015, with a gross margin of -136.1%, an operating margin of -10218.6%, and net income of -$18.1M. In FY2016, revenue was unchanged at $75,000, reflecting revenue growth of 0.0%, with a gross margin of -24.5% and net income of -$8.3M. By FY2024, revenue expanded to $6.4M, generating revenue growth of 8378.7%, a gross margin of 100.0%, an operating margin of -38.8%, and net income of -$3.1M. The two-year revenue CAGR from FY2015 to FY2024 stood at 820.8%. For the trailing twelve months through the latest quarter ended June 30, 2026, revenue was $0, operating margin was 0.0%, and EPS was $3.52.

As of the quarter ended June 30, 2026, Eloxx held $62.0M in cash and short-term investments, with total assets of $63.4M and shareholders' equity of $46.4M. Its liquidity profile shows a current ratio of 3.74. Operating cash flow in FY2024 was -$4.7M, and free cash flow was -$4.7M. For FY2025, capital expenditures totaled $6.3M, while the share count change over 5 years reached 7336.1%.

Eloxx has a market capitalization of $52.6M and an enterprise value of $53.7M. The stock trades at a trailing P/E of 3.7x, compared to a median of 24.6x for its US-listed Healthcare peers. Its price-to-book ratio is 1.2x, and EV to EBITDA is 0.1x versus the US-listed Healthcare peer median of 12.0x. The stock closed at $13.03 on October 16, 2026, within its 52-week range of $8.20 to $23.40. Over broader horizons, the S&P 500 (SPY) returned 16.8% over one year and 83.0% over five years.

Consensus coverage shows 5 Strong Buy ratings, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell recommendations. The mean price target is $38.25, indicating upside of 193.6% compared to the last close of $13.03. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$2.23 on revenue of $0. For the next fiscal year, 4 analysts estimate an EPS of -$2.55 and revenue of $0, with revenue growth projected at 0.0%. The next earnings date is November 10, 2026.

This page is an AI-written research summary of Eloxx Pharmaceuticals, Inc. (ELOX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ELOX income statement, ELOX balance sheet, ELOX key metrics, ELOX analyst forecast, ELOX chart. See the ELOX stock overview for the latest quote and news.